40 related articles for article (PubMed ID: 38560664)
1. Liensinine diperchlorate and artemisitene synergistically attenuate breast cancer progression through suppressing PI3K-AKT signaling and their efficiency in breast cancer patient-derived organoids.
Lin X; Lin T; Liu M; Chen D; Chen J
Biomed Pharmacother; 2024 Jun; 176():116871. PubMed ID: 38861856
[TBL] [Abstract][Full Text] [Related]
2. MTCH2 stimulates cellular proliferation and cycles via PI3K/Akt pathway in breast cancer.
Jiang W; Miao Y; Xing X; Liu S; Xing W; Qian F
Heliyon; 2024 Mar; 10(6):e28172. PubMed ID: 38560664
[TBL] [Abstract][Full Text] [Related]
3. miR-489 inhibits proliferation, cell cycle progression and induces apoptosis of glioma cells via targeting SPIN1-mediated PI3K/AKT pathway.
Li Y; Ma X; Wang Y; Li G
Biomed Pharmacother; 2017 Sep; 93():435-443. PubMed ID: 28666210
[TBL] [Abstract][Full Text] [Related]
4. Curcumol inhibits breast cancer growth
Wei ZL; Juan W; Tong D; Juan LX; Sa LY; Jie HFM; Xiao G; Xiang LG; Jie HM; Xu C
Food Funct; 2023 Jan; 14(2):874-885. PubMed ID: 36537297
[No Abstract] [Full Text] [Related]
5. AKR1B10 promotes breast cancer cell proliferation and migration via the PI3K/AKT/NF-κB signaling pathway.
Qu J; Li J; Zhang Y; He R; Liu X; Gong K; Duan L; Luo W; Hu Z; Wang G; Xia C; Luo D
Cell Biosci; 2021 Aug; 11(1):163. PubMed ID: 34419144
[TBL] [Abstract][Full Text] [Related]
6. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors.
Chang WW; Lin RJ; Yu J; Chang WY; Fu CH; Lai A; Yu JC; Yu AL
Breast Cancer Res; 2013 May; 15(3):R39. PubMed ID: 23663564
[TBL] [Abstract][Full Text] [Related]
7. MTCH2 is a mitochondrial outer membrane protein insertase.
Guna A; Stevens TA; Inglis AJ; Replogle JM; Esantsi TK; Muthukumar G; Shaffer KCL; Wang ML; Pogson AN; Jones JJ; Lomenick B; Chou TF; Weissman JS; Voorhees RM
Science; 2022 Oct; 378(6617):317-322. PubMed ID: 36264797
[TBL] [Abstract][Full Text] [Related]
8. PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance.
Vitale SR; Martorana F; Stella S; Motta G; Inzerilli N; Massimino M; Tirrò E; Manzella L; Vigneri P
Crit Rev Oncol Hematol; 2021 Jun; 162():103334. PubMed ID: 33865994
[TBL] [Abstract][Full Text] [Related]
9. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Rugo HS; Lerebours F; Ciruelos E; Drullinsky P; Ruiz-Borrego M; Neven P; Park YH; Prat A; Bachelot T; Juric D; Turner N; Sophos N; Zarate JP; Arce C; Shen YM; Turner S; Kanakamedala H; Hsu WC; Chia S
Lancet Oncol; 2021 Apr; 22(4):489-498. PubMed ID: 33794206
[TBL] [Abstract][Full Text] [Related]
10. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of mitochondrial carrier homolog 2 (MTCH2) suppresses tumor invasion and enhances sensitivity to temozolomide in malignant glioma.
Yuan Q; Yang W; Zhang S; Li T; Zuo M; Zhou X; Li J; Li M; Xia X; Chen M; Liu Y
Mol Med; 2021 Jan; 27(1):7. PubMed ID: 33509092
[TBL] [Abstract][Full Text] [Related]
12. Cancer Statistics, 2021.
Siegel RL; Miller KD; Fuchs HE; Jemal A
CA Cancer J Clin; 2021 Jan; 71(1):7-33. PubMed ID: 33433946
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
